Recce Pharmaceuticals (ASX:RCE) granted key patent in Israel for anti-infectives RECCE 327 and RECCE 529
Recce Pharmaceuticals achieved a milestone as the State of Israel Patent Office granted a new Patent Family 4 for its anti-infectives, RECCE 327 and RECCE 529, extending until 2041.
The patent covers the preparation process and usage of these anti-infectives for treating various bacterial and viral infections.
It marks Recce's first patent in Israel, a country with a thriving pharmaceutical market valued at US$5.3 billion ($8.14 billion) in 2021.
The development highlights the potential of Recce's products in combating antibiotic-resistant pathogens and emerging viral diseases globally.
#News #ASX #Pharmaceuticals #Israel
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
